Among 10,022 human cancers within The Cancer Genome Atlas, nonsynonymous mutations in NALCN were enriched in gastric, colorectal, lung, prostate and head and neck cancers (Fig. 1c)18,19. This evidence concerns the gene NALCN and head and neck cancer.